Skip to main content
SpringerLink
Log in

Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients

  • Research Article
  • Published:
Genes & Genomics Aims and scope Submit manuscript

Abstract

Background

There is high mortality rate and poor prognosis in lung cancer, especially non-small-cell lung cancer (NSCLC). Recent study showed that concurrent classic driver oncogene mutation with ROS1 rearrangement was found in NSCLC patients. However, whether this would affect the development and prognosis of NSCLC is still unclear.

Objective

To explore the clinical characteristics and prognosis of NSCLC patients harboring concurrent classic driver oncogene mutation with ROS1 rearrangement.

Methods

A retrospective study was conducted on 220 patients diagnosed with NSCLC. All samples were screened for EGFR and KRAS using amplification-refractory mutation system assay, and for ALK, ROS1 using RT-PCR. The clinical characteristics and clinical outcomes of concurrent gene alterations with ROS1 rearrangement were analyzed.

Results

In 220 patients, 12 (5.45%) were ROS1 rearrangement, who tend to be younger, non-smokers. The mutation rates of EGFR, KRAS, ALK and ROS1 in NSCLC were 28.64%, 1.82%, 3.64% and 5.45%, respectively. ROS1 rearrangement was identified to co-occur in 5 (2.27%) NSCLC patients. ROS1/EGFR co-alterations were found in 3.17% of NSCLC patients, 16.67% of ROS1-positive NSCLC patients. Concomitant ROS1/ALK rearrangement constituted 37.50% in ALK-positive patients, and 25.00% in ROS1-positive patients. SDC4-ROS1 was the most common fusion partner in concurrent ROS1 rearrangement patients. The median overall survival of NSCLC with concurrent ROS1 rearrangement group and single ROS1 rearrangement group were 25 months and 14 months.

Conclusion

Concurrent driver oncogenes mutation with ROS1 rearrangement defines a unique subgroup of NSCLC. Patients with concomitant ROS1 rearrangement might have a better prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Acquaviva J, Wong R, Charest A (2009) The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 1795:37–52

    CAS  Google Scholar 

  • Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870

    Article  CAS  Google Scholar 

  • Birchmeier C, Sharma S, Wigler M (1987) Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 84:9270–9274

    Article  CAS  Google Scholar 

  • Cai W, Zhou C, Ren S, Chen X, Gao G, Li X, Li W, Zhao C (2014) Coexistence of Egfr mutations with Alk, Ros1 or Ret rearrangements in lung adenocarcinoma: a clinicopathological analysis from 646 Chinese patients with lung adenocarcinoma. Ann Oncol 25:iv69

    Article  Google Scholar 

  • Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC et al (2014) Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol 9:1171–1179

    Article  CAS  Google Scholar 

  • Cui M, Han Y, Li P, Zhang J, Ou Q, Tong X, Zhao R, Dong N, Wu X, Li W et al (2020) Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Mol Oncol 14:2787–2795

    Article  CAS  Google Scholar 

  • Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M et al (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570–4579

    Article  CAS  Google Scholar 

  • Davies KD, Le AT, Sheren J, Nijmeh H, Gowan K, Jones KL, Varella-Garcia M, Aisner DL, Doebele RC (2018) Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol 13:1474–1482

    Article  Google Scholar 

  • Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18:865–875

    Article  CAS  Google Scholar 

  • Gibelin C, Avrillon V, De La Fouchardiere A, Mc Leer-Florin A, Lantuejoul S, Fayette J (2016) Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas. Lung Cancer 102:42–43

    Article  Google Scholar 

  • Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbe C, Leighl NB, Liu G, Feld R et al (2018) The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Lung Cancer 123:22–29

    Article  Google Scholar 

  • Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS et al (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24:2364–2370

    Article  CAS  Google Scholar 

  • Li Q, Wu J, Yan LX, Huang JW, Zhang Z, Zhang JE, Gao XL, Luo ZR, Liu J, Yang SF et al (2017) ALK and ROS1 double-rearranged lung squamous cell carcinoma responding to Crizotinib treatment: a case report. J Thorac Oncol 12:e193–e197

    Article  Google Scholar 

  • Li X, Cai W, Yang G, Su C, Ren S, Zhao C, Hu R, Chen X, Gao G, Guo Z et al (2017) Comprehensive analysis of EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations. J Thorac Oncol 12:1388–1397

    Article  Google Scholar 

  • Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ et al (2017) ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol 12:872–877

    Article  Google Scholar 

  • Liu C, Yu H, Chang J, Chen H, Li Y, Zhao W, Zhao K, Zhu Z, Sun S, Fan M et al (2019) Crizotinib in Chinese patients with ROS1-rearranged advanced nonsmall-cell lung cancer in routine clinical practice. Target Oncol 14:315–323

    Article  Google Scholar 

  • Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH et al (2016) Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget 7:65185–65195

    Article  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  Google Scholar 

  • Mao Y, Wu S (2017) ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma. Onco Targets Ther 10:3399–3404

    Article  Google Scholar 

  • Nagarajan L, Louie E, Tsujimoto Y, Balduzzi PC, Huebner K, Croce CM (1986) The human c-ros gene (ROS) is located at chromosome region 6q16----6q22. Proc Natl Acad Sci U S A 83:6568–6572

    Article  CAS  Google Scholar 

  • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  CAS  Google Scholar 

  • Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203

    Article  CAS  Google Scholar 

  • Sato S, Nagahashi M, Koike T, Ichikawa H, Shimada Y, Watanabe S, Kikuchi T, Takada K, Nakanishi R, Oki E et al (2018) Impact of concurrent genomic alterations detected by comprehensive genomic sequencing on clinical outcomes in east-Asian patients with EGFR-mutated lung adenocarcinoma. Sci Rep 8:1005

    Article  Google Scholar 

  • Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971

    Article  Google Scholar 

  • Song Z, Zheng Y, Wang X, Su H, Zhang Y, Song Y (2017) ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. J Thorac Dis 9:3919–3926

    Article  Google Scholar 

  • Wen YS, Cai L, Zhang XW, Zhu JF, Zhang ZC, Shao JY, Zhang LJ (2014) Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma. Med (Baltim) 93:e296

    Article  CAS  Google Scholar 

  • Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K et al (2017) High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer. J Thorac Oncol 12:54–64

    Article  Google Scholar 

  • Wu J, Lin Y, He X, Yang H, He P, Fu X, Li G, Gu X (2016) Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. BMC Cancer 16:599

    Article  Google Scholar 

  • Yan X, Wang H, Li P, Zhang G, Zhang M, Yang J, Zhang X, Zheng X, Ma Z (2019) Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Lung Cancer 128:6–12

    Article  Google Scholar 

  • Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY et al (2014) Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 20:1383–1392

    Article  Google Scholar 

  • Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H (2013) ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 37:554–562

    Article  Google Scholar 

  • Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M (2016) ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer 94:22–27

    Article  Google Scholar 

  • Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B (2019) Clinical management of non-small cell lung cancer with concomitant EGFR mutations and ALK rearrangements: efficacy of EGFR tyrosine kinase inhibitors and Crizotinib. Target Oncol 14:169–178

    Article  Google Scholar 

  • Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ et al (2011) Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 29:3316–3321

    Article  CAS  Google Scholar 

  • Zhu YC, Xu CW, Ye XQ, Yin MX, Zhang JX, Du KQ, Zhang ZH, Hu J (2016) Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. Onco Targets Ther 9:4301–4305

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by national public health project (201402024). Special thanks will give to the colleges in the laboratory for kindly providing help in the current study.

Author information

Authors and Affiliations

  1. Department of Respiration, Tangdu Hospital, Air Force Medical University, Xi’an, 710000, China

    Dandan Li, Hua Jiang, Faguang Jin, Lei Pan, Yonghong Xie & Chunmei Li

  2. Medical Team of Chinese People’s Liberation Army of 93932 Unit, Qinghai, 810000, China

    Liang Zhang

Authors
  1. Dandan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hua Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faguang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yonghong Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chunmei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DDL, FGJ and LP conceived and designed the study. HJ and LZ analyzed the data. YHX and CML wrote the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Chunmei Li.

Ethics declarations

Conflict of interest

Dandan Li, Hua Jiang, Faguang Jin, Lei Pan, Yonghong Xie, Liang Zhang and Chunmei Li declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, D., Jiang, H., Jin, F. et al. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients. Genes Genom 45, 93–102 (2023). https://doi.org/10.1007/s13258-022-01326-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13258-022-01326-w

Keywords

Search

Navigation